TARSUS PHARMACEUTICALS INC. overview

Generated $48.1 million in XDEMVY ® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient...

Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its...

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here . A recorded...

IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ Chief...

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts approximately 25 million people in the U.S. – or 1 out of every 12 adults Media accompanying this announcement is available by clicking on this link IRVINE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply...

IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Aziz Mottiwala, Chief Commercial Officer, will participate in a virtual fireside chat at the UBS Virtual Ophthalmology Day 2024 taking place on Wednesday, October 2, at 6:00 a.m. PT / 9:00 a.m. ET. A live webcast and additional...

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference...

Generated $40.8 million in XDEMVY ® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 Management to host conference call today, August 8, 2024 , at 1:30 p.m. P.T. / 4:30 p.m....